Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mereo BioPharma Group plcMREO · Entity 7264 | Director | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mereo BioPharma Group plc
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2036-02-26 | Direct | 66,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 66,000 · Balance 66,000 F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. |
| Deferred Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 96,163 |
Reported balance
After 2026-02-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-26 · Grant · Acquired 96,163 · Balance 96,163 F3: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.
F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F3: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Feb 27, 2026 16:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantDeferred Restricted Stock Units · Derivative | 96,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082826 · ownership.xml · derivative · entry 2 Shames Daniel · CIK 0002005702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,163 Underlying: American Depository Shares · 96,163 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 16:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 66,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001193125-26-082826 · ownership.xml · derivative · entry 1 Shames Daniel · CIK 0002005702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,000 Underlying: American Depositary Shares · 66,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 16:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantDeferred Restricted Stock Units · Derivative | 13,719 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015428 · ownership.xml · derivative · entry 2 Shames Daniel · CIK 0002005702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,719 Underlying: American Depository Shares · 13,719 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 16:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 55,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0000950170-25-015428 · ownership.xml · derivative · entry 1 Shames Daniel · CIK 0002005702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: American Depositary Shares · 55,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 16:15 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantDeferred Restricted Stock Units · Derivative | 14,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-013267 · ownership.xml · derivative · entry 2 Shames Daniel · CIK 0002005702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,139 Underlying: American Depository Shares · 14,139 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 16:15 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 45,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0000950170-24-013267 · ownership.xml · derivative · entry 1 Shames Daniel · CIK 0002005702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: American Depository Shares · 45,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.